BioMarin Pharmaceutical, BMRN and NASDAQ

BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Raised to $113.00
BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) had its target price upped by UBS Group from $109.00 to $113.00 in a research report report published on Thursday,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.
BioMarin Pharmaceutical (NASDAQ:BMRN) Reports Bullish Q4, Stock Soars
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 15.6% year on year to $747.3 million. The company’s full-year revenue guidance of $3.
Wedbush Remains a Buy on BioMarin Pharmaceutical (BMRN)
In a report released today, Yun Zhong from Wedbush maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), with a price
Scotiabank Forecasts Strong Price Appreciation for BioMarin Pharmaceutical (NASDAQ:BMRN) Stock
BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) had its price objective raised by Scotiabank from $78.00 to $80.00 in a research report sent to investors on Thursday,Benzinga reports. They currently have a sector perform rating on the biotechnology company’s stock.
Why BioMarin Pharmaceutical Stock Zoomed Almost 5% Higher Today
BioMarin Pharmaceutical (NASDAQ: BMRN) was a lively stock in the best way on Thursday following the release of its latest set of quarterly results. Enthusiastic investors traded the company's shares up by nearly 5% in price,
Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today
What Happened? Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 9.6% in the pre-market session after the company reported impressive fourth-quarter results, exceeding analysts' sales and EPS estimates.
FierceBiotech2d
As BioMarin searches for 'clever science,' its R&D chief warns innovation could be hit by NIH fund drought
The R&D head is looking for "clever science," which Friberg said is readily apparent in BioMarin’s recent research pact with ...
BioMarin: EPS Surges Past Expectations
BioMarin Pharmaceutical exceeded earnings and revenue expectations in its Q4 2024 financial results.
Demystifying Biomarin Pharmaceutical: Insights From 8 Analyst Reviews
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $94.25, a high estimate of $126.00, and a low estimate of $70.00. This current ...
BioMarin price target raised to $80 from $78 at Scotiabank
Scotiabank raised the firm’s price target on BioMarin (BMRN) to $80 from $78 and keeps a Sector Perform rating on the shares. The firm is ...
BioMarin Pharma Shares Rise After Higher 4Q, Upbeat Outlook
Shares of BioMarin Pharmaceutical climbed after better fourth-quarter earnings and revenue topped analyst views and the company provided upbeat revenue guidance. The stock was up 5% at $68.87 in ...
BioMarin Pharmaceutical Full Year 2024 Earnings: Beats Expectations
Full Year 2024 Results Key Financial Results Revenue: US$2.85b (up 18% from ...
BioMarin price target raised to $113 from $109 at UBS
UBS analyst Eliana Merle raised the firm’s price target on BioMarin (BMRN) to $113 from $109 and keeps a Buy rating on the shares. BioMarin ...
Zacks.com on MSN3d
BioMarin Q4 Earnings & Sales Top Estimates, Stock Up on Upbeat '25 View
BioMarin Pharmaceutical BMRN reported fourth-quarter adjusted earnings per share of 92 cents, which beat the Zacks Consensus ...